Hematology analyzer reagents

InformationRetigabine 2HCl Retigabine 2HCl (D-23129) is a novel anticonvulsant with activity in a broad range of seizure models. The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+)

InformationRetigabine 2HCl Retigabine 2HCl (D-23129) is a novel anticonvulsant with activity in a broad range of seizure models. The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+)

InformationRetigabine 2HCl Retigabine 2HCl (D-23129) is a novel anticonvulsant with activity in a broad range of seizure models. The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+)

InformationRetigabine 2HCl Retigabine 2HCl (D-23129) is a novel anticonvulsant with activity in a broad range of seizure models. The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+)

InformationRetigabine 2HCl Retigabine 2HCl (D-23129) is a novel anticonvulsant with activity in a broad range of seizure models. The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+)

InformationRetigabine 2HCl Retigabine 2HCl (D-23129) is a novel anticonvulsant with activity in a broad range of seizure models. The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+)

InformationRetigabine 2HCl Retigabine 2HCl (D-23129) is a novel anticonvulsant with activity in a broad range of seizure models. The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+)

InformationRetigabine 2HCl Retigabine 2HCl (D-23129) is a novel anticonvulsant with activity in a broad range of seizure models. The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+)

InformationOzagrel HCl (OKY-046) is a selectivethromboxane A(2) (TXA(2)) synthetase inhibitor withIC50of 11 nM for rabbit platelet, used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral

InformationIxazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the20S proteasomewithIC50andKiof 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites,

InformationIpratropium Bromide is an antagonist of M3 typemuscarinic acetylcholine receptors, used for the treatment of chronic obstructive pulmonary disease (COPD).In vitroIpratropium bromide combined with Formoterol partially protects the lungs

Ipratropium Bromide is a muscarinic antagonist, bronchodilator, N-Isopropyl salt of atropine.An N-isopropyl salt of atropine and muscarinic antagonist.